[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590582":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":43,"responsibleParty":62,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":41,"enrollmentInfo":79,"targetDuration":41,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":46,"whyStopped":41,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fluvoxamine","EXPERIMENTAL","100 mg of fluvoxamine on the morning of surgery (POD 0), 100 mg on the evening of surgery (POD 0), 100 mg on the morning of POD 1, and 100 mg on the evening of POD 1. All administered as PO capsules.",[13],"Drug: Fluvoxamine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo capsule on the morning of surgery (POD 0), Placebo capsule on the evening of surgery (POD 0), Placebo capsule on the morning of POD 1, and Placebo capsule on the evening of POD 1. All administered PO.",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","100mg Fluvoxamine Capsule\n\n1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery\n2. Post-operative day 1 - Study drug to be taken morning and evening",[9],[26],"Oral Fluvoxamine 100 mg capsules (immediate release)",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo Capsule\n\n1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery\n2. Post-operative day 1 - Study drug to be taken morning and evening",[15],[31],"microcrystalline cellulose",[33],{"name":34,"affiliation":5,"role":35},"Ben Palanca, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Sarah Knarr","CONTACT","3143622415",null,"knarr.sarah@wustl.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Washington University School of Medicine\u002FBarnes-Jewish Hospital","RECRUITING","St Louis","Missouri","63110","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-90.19789,38.62727,{"lat":56,"lon":55},[59,61],{"name":38,"role":39,"phone":60,"phoneExt":41,"email":42},"314-362-2415",{"name":34,"role":35,"phone":41,"phoneExt":41,"email":41},{"type":35,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Ben J.A. Palanca","Associate Professor",[66],{"name":67,"class":68},"National Institute on Aging (NIA)","NIH","100590582","phase-3-mitigating-delirium-with-fluvoxamine-treatment-for-non-cardiac-surgery-100590582",false,"NCT06969287","Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery","Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery (MD FluNCS)","MD FluNCS","Inclusion Criteria:\n\n* English-speaking\n* elective non-cardiac or non-intracranial surgery requiring at least a 2-day hospital length of stay\n\nExclusion Criteria:\n\n* Received investigational drug within the last 7 weeks\n* lack of capacity to provide informed consent\n* prior known intolerance or allergy to SSRIs or fluvoxamine\n* planned postoperative ventilation\n* drug or alcohol dependence\n* preoperative use of non-NSAID medications with drug-drug interactions of Class X (Avoid Combination) or D (Consider Therapy Modification)\n* risk of serotonin syndrome (St John's Wort, SSRIs, or TCA)","ALL","60 Years",{"count":80,"type":81},46,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","The investigation will establish biological plausibility and infrastructure required for a multisite clinical trial evaluating the re-purposing of fluvoxamine to mitigate postoperative delirium risk in geriatric patients undergoing non-cardiac non-intracranial surgery.",[87,88],"Delirium","Surgery-Complications",[90,91,92,93],"delirium","geriatric","surgery","fluvoxamine","2026-04-24",{"date":96,"type":97},"2026-04-29","ACTUAL",{"date":99,"type":97},"2026-04-06",{"date":101,"type":81},"2028-04-01",{"name":5,"class":6},1]